Obexelimab  (Synonyms: 奥贝利单抗; XmAb5871)

Obexelimab (XmAb5871) is a humanized anti-CD19 antibody. Obexelimab works by inhibiting B cell receptor (BCR) mediated calcium influx and promoting the phosphorylation of Fc γ receptor IIb (FcγRIIb), which reduces B cell activation and function, leading to B cell apoptosis. Obexelimab can be used in research for rheumatoid arthritis and systemic lupus erythematosus^[1][2][3].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Chimeric

Obexelimab 可以诱导凋亡途径相关基因表达水平并促进 B 细胞凋亡^[1]。
Obexelimab (10 μg/mL, 3 min) 通过抑制 BCR 介导的钙通量并促进 FcγRIIb 磷酸化来抑制 B 细胞活化和功能^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Obexelimab (10 mg/kg; 每周 2 次; 腹腔注射) 可以抑制植入类风湿性关节炎 (RA) 患者外周血单个核细胞 (PBMC) 的免疫缺陷小鼠的自身免疫反应^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

1690307-05-1

液体

Colorless to light yellow

奥贝利单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Loaded CD19 Protein, Human (HEK293, His, HY-P74330) on AHC2 biosensor, can bind Obexelimab with an affinity constant of 1.556E-09 M as determined in BLI assay.

• [1]. Boyles JS, et al. A nondepleting anti-CD19 antibody impairs B cell function and inhibits autoimmune diseases. JCI Insight. 2023 Jul 10;8(13):e166137.  [Content Brief]

  [2]. Chu SY, et al. Suppression of rheumatoid arthritis B cells by XmAb5871, an anti-CD19 antibody that coengages B cell antigen receptor complex and Fcγ receptor IIb inhibitory receptor. Arthritis Rheumatol. 2014 May;66(5):1153-64.  [Content Brief]

  [3]. Horton HM, et al. Antibody-mediated coengagement of FcγRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus. J Immunol. 2011 Apr 1;186(7):4223-33.  [Content Brief]